Arrivent Biopharma, Inc.
Clinical trials sponsored by Arrivent Biopharma, Inc., explained in plain language.
-
New hope for rare lung cancer mutation: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) in people with advanced lung cancer that has specific uncommon genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease…
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:54 UTC
-
New hope for advanced cancers: experimental drug MRG007 enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called MRG007 in people with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also seei…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:52 UTC